<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432404</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003584</org_study_id>
    <secondary_id>U19AI113173</secondary_id>
    <nct_id>NCT02432404</nct_id>
  </id_info>
  <brief_title>Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity</brief_title>
  <official_title>Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1
      week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR
      use among women either with BV or at high risk for BV. The investigators will also recruit
      women who are HSV2-infected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of BV-associated bacteria by qPCR and high-throughput sequencing tests</measure>
    <time_frame>Up to 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of vaginal defensins and cytokines</measure>
    <time_frame>Up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of incident BV</measure>
    <time_frame>Up to 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of HSV-2 viral shedding among HSV-2-infected women assessed by PCR</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Cyclic NuvaRing CVR Use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CVR use for 3 weeks, remove for 1 week, then replace</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous NuvaRing CVR Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVR use for 4 weeks, then replace</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NuvaRing</intervention_name>
    <arm_group_label>Cyclic NuvaRing CVR Use</arm_group_label>
    <arm_group_label>Continuous NuvaRing CVR Use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18-40 year old women

          -  BV+ by Amsel criteria and Nugent score OR history of BV in the prior 6 months

          -  Willing to use the NuvaRing as directed

          -  Not intending or wishing to become pregnant over the course of the study

          -  Capable of providing written informed consent

        Exclusion Criteria:

          -  Current pregnancy

          -  Desire/intent to become pregnant over the course of the study

          -  Women who are less than 6 weeks postpartum

          -  Contraindications to hormonal contraceptive use per package insert, including history
             of deep vein thrombosis, smoking in women older than 35 years

          -  Current IUD

          -  Unable to comprehend consent material because of language barrier or psychological
             difficulty
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Johnston, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virology Research Clinic</last_name>
    <phone>206-520-4340</phone>
    <email>vrc@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UW Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol. 2004 Sep;104(3):555-63.</citation>
    <PMID>15339769</PMID>
  </reference>
  <reference>
    <citation>Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008 Jul 31;22(12):1493-501. doi: 10.1097/QAD.0b013e3283021a37. Review.</citation>
    <PMID>18614873</PMID>
  </reference>
  <reference>
    <citation>Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9(6):e1001251. doi: 10.1371/journal.pmed.1001251. Epub 2012 Jun 26.</citation>
    <PMID>22745608</PMID>
  </reference>
  <reference>
    <citation>Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012 Jan;12(1):19-26. doi: 10.1016/S1473-3099(11)70247-X. Epub 2011 Oct 3. Erratum in: Lancet Infect Dis. 2012 Feb;12(2):98.</citation>
    <PMID>21975269</PMID>
  </reference>
  <reference>
    <citation>Vodstrcil LA, Hocking JS, Law M, Walker S, Tabrizi SN, Fairley CK, Bradshaw CS. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013 Sep 4;8(9):e73055. doi: 10.1371/journal.pone.0073055. eCollection 2013. Review.</citation>
    <PMID>24023807</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christine Johnston</investigator_full_name>
    <investigator_title>Assistant Professor, Medicine/Division of Allergy and Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HSV-2</keyword>
  <keyword>Contraceptive Vaginal Ring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

